Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Petros Pharmaceuticals, Inc. (PTPI) had Revenue of $5.11M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$5.11M
Net Income	$-26.80M
Cost of Goods Sold	$1.21M
Gross Profit	$3.90M
Operating Expenses	$22.79M
Operating Income	$-17.68M
Non-Operating Income/Expense	$3.36M
Pre-Tax Income	$-14.32M
Normalized Pre-Tax Income	$-14.32M
Income after Taxes	$-14.32M
Income from Continuous Operations	$-14.32M
Consolidated Net Income/Loss	$-14.32M
Normalized Income after Taxes	$-14.32M
EBIT	$-17.68M
EBITDA	$-11.77M
Weighted-Average Shares Outstanding (Basic)	0.32M
Weighted-Average Shares Outstanding (Diluted)	0.32M
Earnings per Share (EPS) (Basic)	$-83.50
Earnings per Share (EPS) (Diluted)	$-83.50
Balance Sheet Financials
Current Assets	$7.29M
Property, Plant, and Equipment	$0.02M
Long-Term Assets	$3.34M
Total Assets	$10.64M
Current Liabilities	$18.03M
Long-Term Debt	--
Long-Term Liabilities	$0.08M
Total Liabilities	$18.10M
Common Equity	$-7.47M
Tangible Shareholders Equity	$-10.67M
Shareholders Equity	$-7.47M
Common Shares Outstanding	0.42M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-2.60M
Cash Flow from Investing Activities	$-0.02M
Cash Flow from Financial Activities	$-7.00M
Beginning Cash	$13.34M
End Cash	$3.71M
Increase/Decrease in Cash	$-9.63M
Stock-Based Compensation	$0.47M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.40
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	-0.97
Gross Margin	76.28%
Operating Margin	-345.84%
EBIT Margin	-345.84%
EBITDA Margin	-230.22%
Pre-Tax Profit Margin	-280.10%
Profit Margin	-524.20%
Free Cash Flow	$-2.63M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.48
Inventory Turnover	0.90
Receiveable Turnover	12.29
Days Sales in Receivables	29.71
Return on Equity	191.75%
Return on Tangible Equity	134.17%
Return on Assets	-134.63%
Return on Investments	191.75%
Book Value Per Share	$-17.73
Free Cash Flow per Share	$-8.18
Operating Cash Flow per Share	$-8.11

Data from Zacks Investment Research, Inc.